Antithrombin MarketSize and Trends

Antithrombin Market – Market Dynamics

Increasing incidence of coagulation disorders, open heart surgeries, and extracorporeal circulation during hemodialysis is augmenting growth of antithrombin market. According to the Centers for Disease Control and Prevention (CDC), 2015, around 900,000 people is affected from venous thromboembolism every year in the U.S. Furthermore, 5 to 8% of the U.S. population has increased risk of suffering from thrombosis due to one of the several genetic risk factors known as inherited thrombophilia.

Therapeutic drug pipeline or advancements in drug administering technology is also expected to fuel growth of antithrombin market. For instance, Fitusiran (ALN-AT3), developed by Alnylam Pharmaceuticals, Inc., is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT). This therapeutic that can be used for the treatment of hemophilia and rare bleeding disorders (RBDs) is in late stage (Phase 2-phase 3) clinical trial. Moreover, GTC Biotherapeutics, Inc.’s product called as ATryn Antithrombin (Recombinant), derived from human blood donors, is used for hereditary antithrombin deficiency and it recently got market approval in the U.S., thereby significantly contributing to the growth of antithrombin market. Therefore, introduction of new types of antithrombin products with different indication over the forecast period is expected to fuel growth of the global antithrombin market. Furthermore, increasing use of antithrombin in combination with heparin is likely to support the growth of antithrombin market. For instance, heparin resistance in cardiac surgery is likely to create opportunities for use of antithrombin products in anticoagulation therapy.